NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 3, 2011, Pages 163-173

  Vogelmeier, Claus ^a   Banerji, Donald ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

chronic obstructive pulmonary disease; long acting muscarinic antagonist; long acting 2 agonist; NVA237; once daily; QVA149

Indexed keywords

GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; QVA 149; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; XEROSTOMIA;

BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; GLYCOPYRROLATE; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M3; SCOPOLAMINE DERIVATIVES;

EID: 79957802503     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811406001     Document Type: Review

References (45)

1. Aaron S.D. Vandemheen K.L. Fergusson D. Maltais F. Bourbeau J. Goldstein R. (2007) Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146: 545–555.
2. Abrams P. Andersson K.E. Buccafusco J.J. Chapple C. de Groat W.C. Fryer A.D. (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148: 565–578.
3. Ali-Melkkila T. Kanto J. Iisalo E. (1993) Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 37: 633–642.
4. ATS. (2002) ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111–117.
5. Barr R.G. Bourbeau J. Camargo C.A. Ram F.S. (2006) Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61: 854–862.
6. Beeh K.M. Beier J. (2010) The short, the long and the ‘ultra-long–: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 27: 150–159.
7. Beeh K.M. Welte T. Buhl R. (2002) Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 69: 372–379.
8. Bourbeau J. Bartlett S.J. (2008) Patient adherence in COPD. Thorax 63: 831–838.
9. Breekveldt-Postma N.S. Koerselman J. Erkens J.A. Lammers J.W. Herings R.M. (2007) Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 101: 1398–1405.
10. Brusasco V. Hodder R. Miravitlles M. Korducki L. Towse L. Kesten S. (2003) Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58: 399–404.
11. Casaburi R. Briggs D.D. Jr Donohue J.F. Serby C.W. Menjoge S.S. Witek T.J. Jr (2000) The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118: 1294–1302.
12. Casaburi R. Kukafka D. Cooper C.B. Witek T.J. Jr Kesten S. (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127: 809–817.
13. Celli B. ZuWallack R. Wang S. Kesten S. (2003) Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124: 1743–1748.
14. Disse B. Reichl R. Speck G. Traunecker W. Ludwig Rominger K.L. Hammer R. (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52: 537–544.
15. Disse B. Speck G.A. Rominger K.L. Witek T.J. Jr Hammer R. (1999) Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64: 457–464.
16. Donohue J.F. (2005) Minimal clinically important differences in COPD lung function. COPD 2: 111–124.
17. Donohue J.F. van Noord J.A. Bateman E.D. Langley S.J. Lee A. Witek T.J. Jr (2002) A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47–55.
18. Fogarty C. Hattersley H. Di Scala L. Drollmann A. (2011) Bronchodilatory effects of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 105: 334–342.
19. Freeman D. Lee A. Price D. (2007) Efficacy and safety of tiotropium in COPD patients in primary care ’ the SPiRiva Usual CarE (SPRUCE) study. Respir Res 8: 45–45.
20. Johnson M. (1998) The beta-adrenoceptor. Am J Respir Crit Care Med 158: S146's153.
21. Jones P.W. Quirk F.H. Baveystock C.M. (1991) The St George's Respiratory Questionnaire. Respir Med 85(Suppl B): 25–31.
22. Kesten S. Celli B. Decramer M. Leimer I. Tashkin D. (2009) Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 4: 397–409.
23. Kiley J.P. Sri R.J. Croxton T.L. Weinmann G.G. (2005) Challenges associated with estimating minimal clinically important differences in COPD ’ the NHLBI perspective. COPD 2: 43–46.
24. Lipson D.A. (2006) Tiotropium bromide. Int J Chron Obstruct Pulmon Dis 1: 107–114.
25. Mahler D.A. Witek T.J. Jr (2005) The MCID of the transition dyspnea index is a total score of one unit. COPD 2: 99–103.
26. Maltais F. Hamilton A. Marciniuk D. Hernandez P. Sciurba F.C. Richter K. (2005) Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128: 1168–1178.
27. Miravitlles M. Anzueto A. (2009) Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis 4: 185–201.
28. Niewoehner D.E. Rice K. Cote C. Paulson D. Cooper J.A. Jr Korducki L. (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143: 317–326.
29. O'Donnell D.E. Fluge T. Gerken F. Hamilton A. Webb K. Aguilaniu B. (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23: 832–840.
30. Pavkov R. (2010) Characteristics of a new capsule based dry powder inhaler for the effective delivery of indacaterol. Curr Med Res Opin 26: 2527–2533.
31. Roux E. Molimard M. Savineau J.P. Marthan R. (1998) Muscarinic stimulation of airway smooth muscle cells. Gen Pharmacol 31: 349–356.
32. Singh S. Loke Y.K. Furberg C.D. (2008) Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300: 1439–1450.
33. Tashkin D.P. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543–1554.
34. Tashkin D.P. Donohue J.F. Mahler D.A. Huang H. Goodwin E. Schaefer K. (2009a) Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 103: 516–524.
35. Tashkin D.P. Pearle J. Iezzoni D. Varghese S.T. (2009b) Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 6: 17–25.
36. Troosters T. Celli B. Lystig T. Kesten S. Mehra S. Tashkin D.P. (2010) Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 36: 65–73.
37. Van de Maele B. Fabbri L.M. Martin C. Horton R. Dolker M. Overend T. (2010) Cardiovascular safety of QVA149, an inhaled combination of indacaterol and glycopyrronium, compared to indacaterol and placebo in patients with COPD. COPD 7: 418–427.
38. van Noord J.A. Aumann J.L. Janssens E. Verhaert J. Smeets J.J. Mueller A. (2006) Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129: 509–517.
39. van Noord J.A. Bantje T.A. Eland M.E. Korducki L. Cornelissen P.J. (2000) A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 55: 289–294.
40. van Noord J.A. Buhl R. Laforce C. Martin C. Jones F. Dolker M. (2010) QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD. Thorax 65: 1086–1091.
41. Verkindre C. Fukuchi Y. Flemale A. Takeda A. Overend T. Prasad N. (2010) Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 104: 1482–1489.
42. Vogelmeier C. Hederer B. Glaab T. Schmidt M. Rutten-van Moelken M. Beeh K.M. (2010a) Reductions in COPD exacerbations with tiotropium compared to salmeterol. Eur Respir J 36(Suppl 1): abstract P5091.
43. Vogelmeier C. Kardos P. Harari S. Gans S.J. Stenglein S. Thirlwell J. (2008) Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 102: 1511–1520.
44. Vogelmeier C. Verkindre C. Cheung D. Galdiz J.B. Guclu S.Z. Spangenthal S. (2010b) Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 23: 438–444.
45. Yorgancýoðlu A. Mahler D. Iqbal A. Owen R. Higgins M. Kramer B. (2009) Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J 34(Suppl 53): P2028–P2028.